72432-03-2
72432-03-2 structure
- Name: Miglitol
- Chemical Name: Miglitol
- CAS Number: 72432-03-2
- Molecular Formula: C8H17NO5
- Molecular Weight: 207.224
- Catalog: API Hormone and endocrine-regulating drugs Pancreatic hormones and other blood sugar regulating drugs
- Create Date: 2018-09-01 11:54:59
- Modify Date: 2024-01-02 10:11:41
-
Miglitol is an oral anti-diabetic drug that acts by inhibiting the ability of the patient to breakdown complex carbohydrates into glucose.Target: OthersMiglitol is an oral anti-diabetic drug that acts by inhibiting the ability of the patient to breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body. Miglitol inhibits glycoside hydrolase enzymes called alpha-glucosidases. Since miglitol works by preventing digestion of carbohydrates, it lowers the degree of postprandial hyperglycemia. It must be taken at the start of main meals to have maximal effect. Its effect will depend on the amount of non-monosaccharide carbohydrates in a person's diet. Dietary supplementation with miglitol from pre-onset stage in OLETF rats delays the onset and development of diabetes and preserves the insulin secretory function of pancreatic islets [1]. Miglitol was orally administered at 40 mg/100 g of high-fat diet containing 45% kcal as fat to 12-week-old rats for 29 days, and age-matched rats without the agent were used as the respective controls [2].
| Name | Miglitol |
|---|---|
| Synonyms |
BAY m 1099
Miglitol (2R,3R,4R,5S)-1-(2-Hydroxyethyl)-2-(hydroxymethyl)piperidin-3,4,5-triol Diastabol (2R,3R,4R,5S)-1-(2-Hydroxyethyl)-2-(hydroxymethyl)-3,4,5-piperidinetriol EINECS 276-661-6 MFCD00867240 GLYSET Plumarol BAY-m-1099 Seibule (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol N-(2-Hydroxyethyl)moranoline 3,4,5-Piperidinetriol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-, (2R,3R,4R,5S)- BAY 1099 (2R,3R,4R,5S)-1-(2-hydroxyéthyl)-2-(hydroxyméthyl)pipéridine-3,4,5-triol |
| Description | Miglitol is an oral anti-diabetic drug that acts by inhibiting the ability of the patient to breakdown complex carbohydrates into glucose.Target: OthersMiglitol is an oral anti-diabetic drug that acts by inhibiting the ability of the patient to breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body. Miglitol inhibits glycoside hydrolase enzymes called alpha-glucosidases. Since miglitol works by preventing digestion of carbohydrates, it lowers the degree of postprandial hyperglycemia. It must be taken at the start of main meals to have maximal effect. Its effect will depend on the amount of non-monosaccharide carbohydrates in a person's diet. Dietary supplementation with miglitol from pre-onset stage in OLETF rats delays the onset and development of diabetes and preserves the insulin secretory function of pancreatic islets [1]. Miglitol was orally administered at 40 mg/100 g of high-fat diet containing 45% kcal as fat to 12-week-old rats for 29 days, and age-matched rats without the agent were used as the respective controls [2]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 453.7±45.0 °C at 760 mmHg |
| Melting Point | 114ºC |
| Molecular Formula | C8H17NO5 |
| Molecular Weight | 207.224 |
| Flash Point | 284.3±27.4 °C |
| Exact Mass | 207.110672 |
| PSA | 104.39000 |
| LogP | -1.40 |
| Vapour Pressure | 0.0±2.5 mmHg at 25°C |
| Index of Refraction | 1.598 |
| Storage condition | -20°C Freezer |
| Water Solubility | Soluble |
| RIDADR | NONH for all modes of transport |
|---|
|
~95%
72432-03-2 |
| Literature: Wennekes, Tom; Meijer, Alfred J.; Groen, Albert K.; Boot, Rolf G.; Groener, Johanna E.; Van Eijk, Marco; Ottenhoff, Roelof; Bijl, Nora; Ghauharali, Karen; Song, Hang; O'Shea, Tom J.; Liu, Hanlan; Yew, Nelson; Copeland, Diane; Van Den Berg, Richard J.; Van Der Marel, Gijsbert A.; Overkleeft, Herman S.; Aerts, Johannes M. Journal of Medicinal Chemistry, 2010 , vol. 53, # 2 p. 689 - 698 |
|
~%
72432-03-2 |
| Literature: Tetrahedron Letters, , vol. 52, # 29 p. 3802 - 3804 |
|
~65%
72432-03-2 |
| Literature: Concia, Alda Lisa; Lozano, Caries; Castillo, Jose A.; Parella, Teodor; Joglar, Jesus; Clapes, Pere Chemistry - A European Journal, 2009 , vol. 15, # 15 p. 3808 - 3816 |
|
~99%
72432-03-2 |
| Literature: Fouace; Therisod Tetrahedron Letters, 2000 , vol. 41, # 38 p. 7313 - 7315 |
|
~%
72432-03-2 |
| Literature: Journal of Natural Products, , vol. 65, # 2 p. 198 - 202 |
|
~%
72432-03-2 |
| Literature: Tetrahedron Letters, , vol. 52, # 29 p. 3802 - 3804 |
|
~%
72432-03-2 |
| Literature: Tetrahedron Letters, , vol. 52, # 29 p. 3802 - 3804 |
|
~%
72432-03-2 |
| Literature: Tetrahedron Letters, , vol. 52, # 29 p. 3802 - 3804 |
|
~%
72432-03-2 |
| Literature: Tetrahedron Letters, , vol. 41, # 38 p. 7313 - 7315 |
| Precursor 9 | |
|---|---|
| DownStream 0 | |